NZ592444A - Vaccine compositions comprising a mutated factor h binding protein - Google Patents

Vaccine compositions comprising a mutated factor h binding protein

Info

Publication number
NZ592444A
NZ592444A NZ592444A NZ59244409A NZ592444A NZ 592444 A NZ592444 A NZ 592444A NZ 592444 A NZ592444 A NZ 592444A NZ 59244409 A NZ59244409 A NZ 59244409A NZ 592444 A NZ592444 A NZ 592444A
Authority
NZ
New Zealand
Prior art keywords
binding protein
factor
vaccine compositions
mutated factor
seq
Prior art date
Application number
NZ592444A
Other languages
English (en)
Inventor
Rachel Exley
Christoph Tang
Susan M Lea
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Priority to NZ601538A priority Critical patent/NZ601538A/en
Publication of NZ592444A publication Critical patent/NZ592444A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ592444A 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein NZ592444A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819633.9A GB0819633D0 (en) 2008-10-25 2008-10-25 Composition
PCT/GB2009/051439 WO2010046715A1 (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Publications (1)

Publication Number Publication Date
NZ592444A true NZ592444A (en) 2012-11-30

Family

ID=40133849

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ592444A NZ592444A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Country Status (23)

Country Link
US (1) US20120052092A1 (OSRAM)
EP (2) EP3501534B1 (OSRAM)
JP (2) JP5676458B2 (OSRAM)
KR (3) KR20170000390A (OSRAM)
CN (2) CN102245202A (OSRAM)
AU (1) AU2009306114B2 (OSRAM)
BR (1) BRPI0919926A2 (OSRAM)
CA (1) CA2741619A1 (OSRAM)
CO (1) CO6382140A2 (OSRAM)
DK (1) DK3501534T5 (OSRAM)
ES (1) ES2970878T3 (OSRAM)
FI (1) FI3501534T3 (OSRAM)
GB (1) GB0819633D0 (OSRAM)
HR (1) HRP20240226T1 (OSRAM)
HU (1) HUE065348T2 (OSRAM)
LT (1) LT3501534T (OSRAM)
MX (1) MX2011004322A (OSRAM)
NZ (2) NZ592444A (OSRAM)
PL (1) PL3501534T3 (OSRAM)
PT (1) PT3501534T (OSRAM)
RU (1) RU2559528C2 (OSRAM)
SI (1) SI3501534T1 (OSRAM)
WO (1) WO2010046715A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1093517T3 (da) 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011110634A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
CN110845585A (zh) * 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
EP3027206A4 (en) 2013-08-02 2017-03-08 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
EP3172224B1 (en) 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
KR102709811B1 (ko) * 2014-08-20 2024-09-24 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 그의 용도
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020124159A1 (en) 2018-12-21 2020-06-25 Griffith University Compositions, methods and uses for eliciting an immune response
WO2021007365A1 (en) * 2019-07-08 2021-01-14 Crapaud Bio, Inc. Methods of making and using lipooligosaccharide compositions and vaccines
BR112022000739A2 (pt) 2019-07-17 2022-04-12 Gemini Therapeutics Sub Inc Anticorpos de potencialização de fator h e usos dos mesmos
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
EP1855715B1 (en) * 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8039007B2 (en) * 2006-06-29 2011-10-18 J. Craig Venter Institute, Inc. Polypeptides from Neisseria meningitidis
EP3017828A1 (en) * 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
CN110845585A (zh) * 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法

Also Published As

Publication number Publication date
CO6382140A2 (es) 2012-02-15
CN105412920A (zh) 2016-03-23
PT3501534T (pt) 2024-02-07
AU2009306114A1 (en) 2010-04-29
JP6076326B2 (ja) 2017-02-08
KR20190011836A (ko) 2019-02-07
DK3501534T3 (da) 2024-02-05
RU2011120706A (ru) 2012-11-27
SI3501534T1 (sl) 2024-03-29
EP2355845A1 (en) 2011-08-17
LT3501534T (lt) 2024-03-12
ES2970878T3 (es) 2024-05-31
KR20110092282A (ko) 2011-08-17
MX2011004322A (es) 2011-06-16
GB0819633D0 (en) 2008-12-03
KR20170000390A (ko) 2017-01-02
BRPI0919926A2 (pt) 2016-02-16
HUE065348T2 (hu) 2024-05-28
EP3501534B1 (en) 2023-11-29
NZ601538A (en) 2014-01-31
DK3501534T5 (da) 2024-09-02
EP3501534A1 (en) 2019-06-26
JP2015063558A (ja) 2015-04-09
CA2741619A1 (en) 2010-04-29
US20120052092A1 (en) 2012-03-01
JP5676458B2 (ja) 2015-02-25
WO2010046715A1 (en) 2010-04-29
RU2559528C2 (ru) 2015-08-10
AU2009306114B2 (en) 2015-10-01
EP2355845B1 (en) 2018-12-05
FI3501534T3 (fi) 2024-02-09
HRP20240226T1 (hr) 2024-05-10
CN102245202A (zh) 2011-11-16
JP2012506411A (ja) 2012-03-15
PL3501534T3 (pl) 2024-04-02

Similar Documents

Publication Publication Date Title
NZ592444A (en) Vaccine compositions comprising a mutated factor h binding protein
PH12018501517B1 (en) Neisseria meningitidis compositions and methods thereof
NZ622048A (en) Hybrid polypeptides including meningococcal fhbp sequences
WO2010127172A3 (en) Chimeric factor h binding proteins (fhbp) and methods of use
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ598351A (en) Il-17 binding compounds and medical uses thereof
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
EP3444352A3 (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2009023300A3 (en) Mutants of cholesterol-dependent cytolysins and uses thereof
NZ603200A (en) Peptides and their use
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
NZ701125A (en) Improved chymosine enzyme variants
NZ597923A (en) Protein glycosylation
EP4417256A3 (en) Materials and methods for improving lung function
NZ586430A (en) Mutant forms of streptolysin o (slo)
NZ601488A (en) Immunogenic proteins and compositions
NZ594268A (en) Grass peptides for vaccine
WO2009072555A1 (ja) 癌ワクチン
NZ614064A (en) Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
PH12013502292A1 (en) Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
AU2011350442B2 (en) Modified tamavidin
GB201211586D0 (en) Japanese cedar peptides for preventing or treating allergy
吴雪莲 Let’s live in a world full of understanding!

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 OCT 2016 BY FB RICE

Effective date: 20131018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2017 BY RENEWALS TEAM

Effective date: 20161018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2018 BY RENEWALS TEAM

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2019 BY SERVICE TEAM

Effective date: 20180730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2020 BY RENEWALS TEAM

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2021 BY RENEWALS TEAM

Effective date: 20201019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2022 BY RENEWALS TEAM

Effective date: 20211023

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2023 BY ENVOY

Effective date: 20221014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2024 BY ANAQUA SERVICES

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2025 BY ANAQUA SERVICES

Effective date: 20240920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2026 BY ANAQUA SERVICES

Effective date: 20250924